



TCR² Therapeutics to Participate in Two Upcoming Conferences in June

June 1, 2022

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate at two upcoming conferences in June in New York.

- Alfonso Quintás-Cardama, Chief Medical Officer of TCR² Therapeutics, will present an update on Company progress at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00PM E.T.
- Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will participate in a panel at the Truist Securities Life Sciences Symposia-cel on Tuesday, June 28, 2022 at 12:00PM E.T.

A live webcast of the presentation will be available on the Investors page of the Company's website at <https://investors.tcr2.com/>. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC[®]-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com



Source: TCR² Therapeutics